Delivering Breakthrough

Therapeutics

About Us

MyMD Pharmaceuticals, Inc. is an early-stage development company pursuing the  discovery of mechanisms of diseases that affect an aging population, followed by implementation of treatments to prevent or cure them.

Our working hypothesis is that an excessive accumulation of reactive oxygen species (ROS) within the cell contributes to the development of different types of diseases that are known to increase with aging, such as autoimmune diseases and cancers.

Aided by advances in the understanding of cell biology and drug design, we focus on designing therapies that target the root of the disease, at the intracellular level. In particular, we aim to achieve a significant improvement over therapies that are more toxic or affect only the symptoms of the disease, rather than its causes.

DRUG DEVELOPMENT

Through our commitment to patients suffering from devastating diseases, MyMD is developing a platform of potential products based on our proprietary small molecule.

MyMD’s early stage development program emphasizes collaboration with a team of highly experienced professionals and partner companies. We believe that our collaborative strategy supports cost-effective potential product innovation and accelerated drug development.

The company has developed a proprietary small molecule, which modifies the pathologic effects of Reactive Oxygen Species through regulation of Hydrogen Peroxide. Recent scientific findings have implicated a strong relationship between ROS accumulation and the initiation and progression of autoimmunity.

We are advancing rapidly toward the filing of an Investigational New Drug Application with the FDA for our lead candidate. At the same time, we are developing preclinical programs in other conditions. Our approach could revolutionize treatment for other autoimmune disorders where the underlying pathology also may be driven or enhanced by ROS . These disorders often have a high unmet need for safe, effective therapies.

Reactive oxygen species in organ-specific autoimmunity.

Di Dalmazi G1,2, Hirshberg J3, Lyle D3, Freij JB4, Caturegli P5,6. Auto Immun Highlights.2016 Dec;7(1):11. doi: 10.1007/s13317-016-0083-0.

 

We are happy to answer any questions you may have about our company and for our exciting, breakthrough therapeutics. We are open to expressions of interest with respect to partnership at all stages of development. For more information, please fill out the form below and we will be in touch with you shortly.










 MYMD-WP-logo-white-trans

324 South Hyde Park Ave Suite 350, Tampa, FL 33606